Manufacturer for Intravitreal Vancomycin - GnRH Antagonist Used for Peptides Synthesis – Gentolex
Manufacturer for Intravitreal Vancomycin - GnRH Antagonist Used for Peptides Synthesis – Gentolex Detail:
Product Detail
|
NO |
Products |
CAS No. |
Application |
Key Quality Indicator |
||||
|
Purity |
Isomer |
Specific impurity |
*Max1 |
Moisture |
||||
|
1 |
Fmoc-3-(2-naphthyl)-D-Ala-OH |
138774-94-4 |
Most products |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
2 |
Ac-3-(2-naphthyl)-D-Ala-OH |
37440-01-0 |
Most products |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
3 |
Fmoc-3-(3-pyridinyl)-D-Ala-OH |
142994-45-4 |
Most products |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
4 |
Fmoc-4-chloro-D-Phe-OH |
142994-19-2 |
Most products |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
5 |
Fmoc-D-Cit-OH |
200344-33-8 |
Cetrorelix |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
6 |
Fmoc-D-Ala-OH.H2O |
79990-15-1 |
Most products |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤6.5% |
|
7 |
Fmoc-D-Aph(tBuCbm)-OH |
1433975-21-3 |
Degarelix |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
8 |
Fmoc-D-Aph(Cbm)-OH |
324017-22-3 |
Degarelix |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
9 |
Fmoc-L-Aph(L-Hor)-OH |
1253282-31-3 |
Degarelix |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
10 |
Fmoc-L-Lys(iPr,Boc)-OH |
201003-48-7 |
Degarelix |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
11 |
Fmoc-N-Me-Tyr(tBu)-OH |
133373-24-7 |
Abarelix |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
12 |
Fmoc-D-Asn(Trt)-OH |
180570-71-2 |
Abarelix |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
13 |
Fmoc-HomoArg(Et)2-OH.HCl |
1864003-26-8 |
Ganirelix |
≥95.0% |
≤0.5% |
≤1.0% |
≤2.0% |
≤2.0% |
|
14 |
Fmoc-D-HomoArg(Et)2-OH.HCl |
2098497-24-4 |
Ganirelix |
≥95.0% |
≤0.5% |
≤1.0% |
≤2.0% |
≤2.0% |
|
15 |
Fmoc-Lys(nicotinoyl)-OH |
252049-11-9 |
Antide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
16 |
Fmoc-D-Lys(nicotinoyl)-OH |
252049-12-0 |
Antide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
* Max1 = Max Unknown Impurity
Other Indicator:
- Acetic Acid: ≤0.02% (All Products)
- Ethyl Acetate: ≤0.5% (All Products)
- Alcohol: ≤0.5% (All Products)
TOC and Conductivity
TOC and conductivity of main supply and return points are monitored periodically. TOC is monitored by QC on every week. Conductivity is monitored online and recorded by purified water station operator once every four hours. The conductivity is monitored at the primary RO, secondary RO, EDI and total return point of distribution system. The specification of purified water is in place and conforms to pre-defined specification which no more than 1.3 µs/cm at 25°C (USP). For main supply and return points, full test. is performed every week, for other using point in the circulating loop, full test is performed once every month. The full test includes characters, pH, nitrate, nitrite, ammonia, conductivity, TOC, non-volatile substances, heavy metals, microbial limits and bacterial endotoxin.
Product detail pictures:
Related Product Guide:
Our organization insists all along the quality policy of "product quality is base of business survival; purchaser gratification is the staring point and ending of an business; persistent improvement is eternal pursuit of staff" as well as the consistent purpose of "reputation 1st, purchaser first" for Manufacturer for Intravitreal Vancomycin - GnRH Antagonist Used for Peptides Synthesis – Gentolex , The product will supply to all over the world, such as: Barbados, Denmark, Uganda, We have a strict and complete quality control system, which ensures that each product can meet quality requirements of customers. Besides, all of our products have been strictly inspected before shipment.
By Adelaide from Bulgaria - 2018.08.12 12:27
The company can keep up with the changes in this industry market, product updates fast and the price is cheap, this is our second cooperation, it's good.
By Diego from Pakistan - 2018.10.09 19:07
